Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

BACKGROUND: Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen, which can be converted to activated TAFI (TAFIa) through proteolytic cleavage by thrombin, plasmin, and most effectively thrombin in complex with the endothelial cofactor thrombomodulin (TM). TAFIa is a carboxypeptid...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Bazzi, Zainab A., Lanoue, Danielle, El-Youssef, Mouhanned, Romagnuolo, Rocco, Tubman, Janice, Cavallo-Medved, Dora, Porter, Lisa A., Boffa, Michael B.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879731/
https://ncbi.nlm.nih.gov/pubmed/27221823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2359-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki